07:37 EST Regenxbio (RGNX) down 35% to $8.59 after FDA places clinical hold on RGX-111
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RGNX:
- Regenxbio announces FDA places clinical hold of RGX-111
- Regenxbio assumed with an Overweight at Barclays
- RegenXBio: Advancing Gene Therapy Pipeline and Near‑Term Regulatory Catalysts Underpin Buy Rating
- Regenxbio highlights progress, anticipated milestones
- Regenxbio price target raised to $28 from $20 at BofA